EMA Authorised: Bimzelx (bimekizumab) — UCB Pharma S.A.

View source ↗

Summary

The EMA authorised Bimzelx (bimekizumab) from UCB Pharma S.A. for psoriasis, with a decision date of 28 April 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BIMZELX (BIMEKIZUMAB)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: UCB Pharma S.A.. Decision date: 28/04/2025